AGF Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3M Buy
4,819
+4,404
+1,061% +$3M 0.01% 390
2026
Q1
$321K Sell
415
-5
-1% -$3.83K ﹤0.01% 617
2025
Q4
$324K Sell
420
-10
-2% -$6.79K ﹤0.01% 621
2025
Q3
$242K Sell
430
-15
-3% -$8.48K ﹤0.01% 637
2025
Q2
$234K Sell
445
-798
-64% -$445K ﹤0.01% 615
2025
Q1
$788K Sell
1,243
-34
-3% -$23.4K ﹤0.01% 560
2024
Q4
$910K Buy
1,277
+942
+281% +$791K ﹤0.01% 581
2024
Q3
$352K Sell
335
-6
-2% -$6.68K ﹤0.01% 649
2024
Q2
$358K Sell
341
-815
-71% -$790K ﹤0.01% 657
2024
Q1
$1.11M Buy
1,156
+428
+59% +$407K 0.01% 561
2023
Q4
$639K Buy
+728
New +$600K ﹤0.01% 606
2023
Q1
Sell
-437
Closed -$315K 805
2022
Q4
$315K Buy
+437
New +$322K ﹤0.01% 725

Other funds holding REGN

AGF Management's REGN Position: Q2 2026 in Review

AGF Management increased its Regeneron Pharmaceuticals (REGN) stake by 1,061% in Q2 2026, buying an estimated $3M and bringing the position to 4,819 shares worth $3M. The position accounts for 0.01% of the portfolio, ranked #390.

AGF Management first reported a position in REGN in Q4 2022 and has held it in 12 quarters since. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • AGF Management held 4,819 shares of Regeneron Pharmaceuticals worth $3M as of Q2 2026.
  • AGF Management bought 4,404 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3M.
  • Regeneron Pharmaceuticals made up 0.01% of AGF Management's portfolio in Q2 2026, its #390 holding.
  • AGF Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on AGF Management's 13F filing for Q2 2026, filed 10 Aug 2026.